The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs
Abstract Herpes simplex virus (HSV) infections are common but there is no vaccine available. We evaluated cationic liposome–DNA complexes (CLDC) as an adjuvant for an HSV gD2 vaccine and compared it to an MPL/Alum adjuvant in a guinea pig model of genital herpes. The addition of CLDC to the gD2 vacc...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2010-05, Vol.28 (21), p.3748-3753 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3753 |
|---|---|
| container_issue | 21 |
| container_start_page | 3748 |
| container_title | Vaccine |
| container_volume | 28 |
| creator | Bernstein, David I Farley, Nicholas Bravo, Fernando J Earwood, Julie McNeal, Monica Fairman, Jeff Cardin, Rhonda |
| description | Abstract Herpes simplex virus (HSV) infections are common but there is no vaccine available. We evaluated cationic liposome–DNA complexes (CLDC) as an adjuvant for an HSV gD2 vaccine and compared it to an MPL/Alum adjuvant in a guinea pig model of genital herpes. The addition of CLDC to the gD2 vaccine significantly decreased acute and recurrent disease and most importantly the number of days with recurrent virus shedding compared to gD2 alone. Reductions in these outcomes were also detected when gD2 + CLDC was compared to gD2 + MPL/Alum. When the vaccine and adjuvants were evaluated as therapeutic vaccines, they were ineffective. CLDC enhanced protection compared to MPL/Alum and is the first vaccine to reduce recurrent virus shedding, a key to decreasing the spread of HSV-2. |
| doi_str_mv | 10.1016/j.vaccine.2009.10.025 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2862079</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0264410X09015424</els_id><sourcerecordid>733640283</sourcerecordid><originalsourceid>FETCH-LOGICAL-c611t-c0d0d6fe109f649883561961679f185f8d60ae0d5be5efc970875254c842ca13</originalsourceid><addsrcrecordid>eNqFkk2P0zAQhiMEYsvCTwBZQohTy9jxR3xZhLp8SZU40AM3y-tMWpfUCXZS0X-PS6Nd2MuebI2feT0z7xTFSwoLClS-2y0O1jkfcMEAdI4tgIlHxYxWqpwzQavHxQyY5HNO4cdF8SylHQCIkuqnxQXVlVBcwKzYrLdIbL0bDzYMZLm6XhIfXESbMJE-dgO6wXeBdA2xZIuxz-Hk932Lv8lw7JEwsmmPrvuL-kCuyVRWliGbMV8s6f0mPS-eNLZN-GI6L4v1p4_r5Zf56tvnr8sPq7mTlA5zBzXUskEKupFcV1UpJNWSSqUbWommqiVYhFrcoMDGaQWVEkxwV3HmLC0vi6uzbD_e7LF2GIZoW9NHv7fxaDrrzf8vwW_NpjsYVkkGSmeBt5NA7H6NmAaz98lh29qA3ZiM4hJA5rIeJstScmBVmcnX98hdN8aQx2Ao16rU2QnIlDhTLnYpRWxuq6ZgTpabnZlma06Wn8LZ8pz36t-W77ImjzPwZgJscrZtog3Op1uOMcW5UjJz788cZn8OHqNJzmNwWPuYt8DUnX-wlKt7Cq71wedPf-IR013XJjED5vtpP0_rCRqo4IyXfwDn6OEL</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1497394500</pqid></control><display><type>article</type><title>The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bernstein, David I ; Farley, Nicholas ; Bravo, Fernando J ; Earwood, Julie ; McNeal, Monica ; Fairman, Jeff ; Cardin, Rhonda</creator><creatorcontrib>Bernstein, David I ; Farley, Nicholas ; Bravo, Fernando J ; Earwood, Julie ; McNeal, Monica ; Fairman, Jeff ; Cardin, Rhonda</creatorcontrib><description>Abstract Herpes simplex virus (HSV) infections are common but there is no vaccine available. We evaluated cationic liposome–DNA complexes (CLDC) as an adjuvant for an HSV gD2 vaccine and compared it to an MPL/Alum adjuvant in a guinea pig model of genital herpes. The addition of CLDC to the gD2 vaccine significantly decreased acute and recurrent disease and most importantly the number of days with recurrent virus shedding compared to gD2 alone. Reductions in these outcomes were also detected when gD2 + CLDC was compared to gD2 + MPL/Alum. When the vaccine and adjuvants were evaluated as therapeutic vaccines, they were ineffective. CLDC enhanced protection compared to MPL/Alum and is the first vaccine to reduce recurrent virus shedding, a key to decreasing the spread of HSV-2.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2009.10.025</identifier><identifier>PMID: 19857450</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Adjuvant ; Adjuvants ; Adjuvants, Immunologic - pharmacology ; Allergy and Immunology ; Alum Compounds - pharmacology ; Animals ; Antibodies, Viral - blood ; Applied microbiology ; Biological and medical sciences ; CLDC ; Deoxyribonucleic acid ; Design ; DNA ; Female ; Fundamental and applied biological sciences. Psychology ; Genital herpes ; Guinea pig ; Guinea Pigs ; Herpes Genitalis - immunology ; Herpes Genitalis - prevention & control ; Herpes simplex virus 2 ; Herpes Simplex Virus Vaccines - immunology ; Herpesvirus 2, Human - immunology ; Hogs ; HSV vaccine ; Lactose ; Lipids ; Liposomes - immunology ; Microbiology ; Miscellaneous ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Viral Envelope Proteins - immunology ; Virology ; Virus Shedding</subject><ispartof>Vaccine, 2010-05, Vol.28 (21), p.3748-3753</ispartof><rights>Elsevier Ltd</rights><rights>2009 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Elsevier Limited May 7, 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c611t-c0d0d6fe109f649883561961679f185f8d60ae0d5be5efc970875254c842ca13</citedby><cites>FETCH-LOGICAL-c611t-c0d0d6fe109f649883561961679f185f8d60ae0d5be5efc970875254c842ca13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X09015424$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22744776$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19857450$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bernstein, David I</creatorcontrib><creatorcontrib>Farley, Nicholas</creatorcontrib><creatorcontrib>Bravo, Fernando J</creatorcontrib><creatorcontrib>Earwood, Julie</creatorcontrib><creatorcontrib>McNeal, Monica</creatorcontrib><creatorcontrib>Fairman, Jeff</creatorcontrib><creatorcontrib>Cardin, Rhonda</creatorcontrib><title>The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Herpes simplex virus (HSV) infections are common but there is no vaccine available. We evaluated cationic liposome–DNA complexes (CLDC) as an adjuvant for an HSV gD2 vaccine and compared it to an MPL/Alum adjuvant in a guinea pig model of genital herpes. The addition of CLDC to the gD2 vaccine significantly decreased acute and recurrent disease and most importantly the number of days with recurrent virus shedding compared to gD2 alone. Reductions in these outcomes were also detected when gD2 + CLDC was compared to gD2 + MPL/Alum. When the vaccine and adjuvants were evaluated as therapeutic vaccines, they were ineffective. CLDC enhanced protection compared to MPL/Alum and is the first vaccine to reduce recurrent virus shedding, a key to decreasing the spread of HSV-2.</description><subject>Adjuvant</subject><subject>Adjuvants</subject><subject>Adjuvants, Immunologic - pharmacology</subject><subject>Allergy and Immunology</subject><subject>Alum Compounds - pharmacology</subject><subject>Animals</subject><subject>Antibodies, Viral - blood</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>CLDC</subject><subject>Deoxyribonucleic acid</subject><subject>Design</subject><subject>DNA</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Genital herpes</subject><subject>Guinea pig</subject><subject>Guinea Pigs</subject><subject>Herpes Genitalis - immunology</subject><subject>Herpes Genitalis - prevention & control</subject><subject>Herpes simplex virus 2</subject><subject>Herpes Simplex Virus Vaccines - immunology</subject><subject>Herpesvirus 2, Human - immunology</subject><subject>Hogs</subject><subject>HSV vaccine</subject><subject>Lactose</subject><subject>Lipids</subject><subject>Liposomes - immunology</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Viral Envelope Proteins - immunology</subject><subject>Virology</subject><subject>Virus Shedding</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk2P0zAQhiMEYsvCTwBZQohTy9jxR3xZhLp8SZU40AM3y-tMWpfUCXZS0X-PS6Nd2MuebI2feT0z7xTFSwoLClS-2y0O1jkfcMEAdI4tgIlHxYxWqpwzQavHxQyY5HNO4cdF8SylHQCIkuqnxQXVlVBcwKzYrLdIbL0bDzYMZLm6XhIfXESbMJE-dgO6wXeBdA2xZIuxz-Hk932Lv8lw7JEwsmmPrvuL-kCuyVRWliGbMV8s6f0mPS-eNLZN-GI6L4v1p4_r5Zf56tvnr8sPq7mTlA5zBzXUskEKupFcV1UpJNWSSqUbWommqiVYhFrcoMDGaQWVEkxwV3HmLC0vi6uzbD_e7LF2GIZoW9NHv7fxaDrrzf8vwW_NpjsYVkkGSmeBt5NA7H6NmAaz98lh29qA3ZiM4hJA5rIeJstScmBVmcnX98hdN8aQx2Ao16rU2QnIlDhTLnYpRWxuq6ZgTpabnZlma06Wn8LZ8pz36t-W77ImjzPwZgJscrZtog3Op1uOMcW5UjJz788cZn8OHqNJzmNwWPuYt8DUnX-wlKt7Cq71wedPf-IR013XJjED5vtpP0_rCRqo4IyXfwDn6OEL</recordid><startdate>20100507</startdate><enddate>20100507</enddate><creator>Bernstein, David I</creator><creator>Farley, Nicholas</creator><creator>Bravo, Fernando J</creator><creator>Earwood, Julie</creator><creator>McNeal, Monica</creator><creator>Fairman, Jeff</creator><creator>Cardin, Rhonda</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20100507</creationdate><title>The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs</title><author>Bernstein, David I ; Farley, Nicholas ; Bravo, Fernando J ; Earwood, Julie ; McNeal, Monica ; Fairman, Jeff ; Cardin, Rhonda</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c611t-c0d0d6fe109f649883561961679f185f8d60ae0d5be5efc970875254c842ca13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adjuvant</topic><topic>Adjuvants</topic><topic>Adjuvants, Immunologic - pharmacology</topic><topic>Allergy and Immunology</topic><topic>Alum Compounds - pharmacology</topic><topic>Animals</topic><topic>Antibodies, Viral - blood</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>CLDC</topic><topic>Deoxyribonucleic acid</topic><topic>Design</topic><topic>DNA</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Genital herpes</topic><topic>Guinea pig</topic><topic>Guinea Pigs</topic><topic>Herpes Genitalis - immunology</topic><topic>Herpes Genitalis - prevention & control</topic><topic>Herpes simplex virus 2</topic><topic>Herpes Simplex Virus Vaccines - immunology</topic><topic>Herpesvirus 2, Human - immunology</topic><topic>Hogs</topic><topic>HSV vaccine</topic><topic>Lactose</topic><topic>Lipids</topic><topic>Liposomes - immunology</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Viral Envelope Proteins - immunology</topic><topic>Virology</topic><topic>Virus Shedding</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bernstein, David I</creatorcontrib><creatorcontrib>Farley, Nicholas</creatorcontrib><creatorcontrib>Bravo, Fernando J</creatorcontrib><creatorcontrib>Earwood, Julie</creatorcontrib><creatorcontrib>McNeal, Monica</creatorcontrib><creatorcontrib>Fairman, Jeff</creatorcontrib><creatorcontrib>Cardin, Rhonda</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bernstein, David I</au><au>Farley, Nicholas</au><au>Bravo, Fernando J</au><au>Earwood, Julie</au><au>McNeal, Monica</au><au>Fairman, Jeff</au><au>Cardin, Rhonda</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2010-05-07</date><risdate>2010</risdate><volume>28</volume><issue>21</issue><spage>3748</spage><epage>3753</epage><pages>3748-3753</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Abstract Herpes simplex virus (HSV) infections are common but there is no vaccine available. We evaluated cationic liposome–DNA complexes (CLDC) as an adjuvant for an HSV gD2 vaccine and compared it to an MPL/Alum adjuvant in a guinea pig model of genital herpes. The addition of CLDC to the gD2 vaccine significantly decreased acute and recurrent disease and most importantly the number of days with recurrent virus shedding compared to gD2 alone. Reductions in these outcomes were also detected when gD2 + CLDC was compared to gD2 + MPL/Alum. When the vaccine and adjuvants were evaluated as therapeutic vaccines, they were ineffective. CLDC enhanced protection compared to MPL/Alum and is the first vaccine to reduce recurrent virus shedding, a key to decreasing the spread of HSV-2.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>19857450</pmid><doi>10.1016/j.vaccine.2009.10.025</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2010-05, Vol.28 (21), p.3748-3753 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2862079 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adjuvant Adjuvants Adjuvants, Immunologic - pharmacology Allergy and Immunology Alum Compounds - pharmacology Animals Antibodies, Viral - blood Applied microbiology Biological and medical sciences CLDC Deoxyribonucleic acid Design DNA Female Fundamental and applied biological sciences. Psychology Genital herpes Guinea pig Guinea Pigs Herpes Genitalis - immunology Herpes Genitalis - prevention & control Herpes simplex virus 2 Herpes Simplex Virus Vaccines - immunology Herpesvirus 2, Human - immunology Hogs HSV vaccine Lactose Lipids Liposomes - immunology Microbiology Miscellaneous Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Viral Envelope Proteins - immunology Virology Virus Shedding |
| title | The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T10%3A59%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20adjuvant%20CLDC%20increases%20protection%20of%20a%20herpes%20simplex%20type%202%20glycoprotein%20D%20vaccine%20in%20guinea%20pigs&rft.jtitle=Vaccine&rft.au=Bernstein,%20David%20I&rft.date=2010-05-07&rft.volume=28&rft.issue=21&rft.spage=3748&rft.epage=3753&rft.pages=3748-3753&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2009.10.025&rft_dat=%3Cproquest_pubme%3E733640283%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1497394500&rft_id=info:pmid/19857450&rft_els_id=1_s2_0_S0264410X09015424&rfr_iscdi=true |